Episode Details

Back to Episodes
The Largest Glaucoma Genome Study Yet Found 29 New Genetic Clues — Could Existing Drugs Target Some of Them?

The Largest Glaucoma Genome Study Yet Found 29 New Genetic Clues — Could Existing Drugs Target Some of Them?

Published 1 month, 2 weeks ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/the-largest-glaucoma-genome-study-yet-found-29-new-genetic-clues-could-existing-drugs-target-some-of-them

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

The Largest Glaucoma Genome Study Yet Found 29 New Genetic Clues — Could Existing Drugs Target Some of Them? The short answer is possibly—but the study did not identify a ready-made glaucoma drug. It found genetic associations that point toward several plausible disease mechanisms, including extracellular-matrix remodeling, aqueous-fluid outflow, cellular stress responses and retinal ganglion-cell survival. Among the four highlighted drug targets, the mammalian target of rapamycin pathway has the strongest combination of genetic, experimental and drug-delivery evidence. Even there, the right direction and amount of treatment remain uncertain. A critical distinction: a gene associated with glaucoma is not automatically a treatment target. The genetic finding may not reveal what the variant does, which eye cell it affects, or whether a drug should increase or decrease the gene’s activity. The paper itself cautions that, for most of these associations, pharmacological direction cannot yet be predicted. () This article distinguishes established evidence—what the studies directly report—from strong inference and informed speculation about possible treatments. What the study actually found The Communications Biology paper was published online on September 23, 2026. Its early-access version is peer reviewed but still described by the publisher as an article in press that may receive further edits. It is a genetic-association study, not a clinical trial. () Cohorts and ancestry For the full table, please open this article on visualfieldtest.com. The discovery and replication sequencing analyses were restricted to participants of European ancestry. The paper says 464,778 European-ancestry participants made up about 95% of its UK Biobank whole-genome-sequencing resource. The All of Us replication sample was also European ancestry. FinnGen represents a Finnish population, while the Million Veteran Program is ancestrally diverse overall, but the study’s cited open-angle-glaucoma analysis used its European-ancestry results. Thus, the large headline sample does not mean that the principal discovery and replication findings were tested across equally large, diverse ancestry groups. () The authors also report a preliminary UK Biobank pan-ancestry analysis that found 15 additional significant variants—11 rare and four common. They had external replication evidence for only one of those, a common variant near ADGRB2. The authors note that many signals were not present or testable in current external datasets. () Important caveat: the replication phenotype was broader than the discovery phenotype In UK Biobank, cases were identified from self-reported glaucoma and medical-record codes, with secondary forms excluded. In All of Us, the researchers used medical-record codes for glaucoma because that definition had more cases and greater statistical power than the smaller primary open-angle glaucoma-specific definition. This means the replication check was not a perfect match to the primary open-angle glaucoma discovery phenotype. FinnGen used a primary open-angle glaucoma endpoint; the Million Veteran Program used an open-angle-glaucoma phenotype. () That does not invalidate the replication evidence, but it makes the word “replication” less straightforward than it ma

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us